Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans

Infection and Immunity

Volumn 74, Issue 6, 2006, Pages 3096-3106

  Gates, Marcellene A ^a   Kozel, Thomas R ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 ANTIBODY; FLUORESCENT DYE; MICROSPHERE; MONOCLONAL ANTIBODY; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CAPSULAR MATRIX; CELL STRUCTURE; COMPLEMENT ACTIVATION; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DENSITY; ENCAPSULATION; FUNGAL VIRULENCE; GUINEA PIG; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RODENT; SERUM; YEAST CELL;

ANIMALS; BACTERIAL CAPSULES; COMPLEMENT ACTIVATION; COMPLEMENT C3; CRYPTOCOCCUS NEOFORMANS; GUINEA PIGS; HUMANS; MICE; POLYSACCHARIDES; RATS; SPECIES SPECIFICITY;

EID: 33646916874     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01213-05     Document Type: Article

References (37)

1. Alsenz, J., D. Avila, H. P. Huemer, I. Esparza, J. D. Becherer, T. Kinoshita, Y. Wang, S. Oppermann, and J. D. Lambris. 1992. Phylogeny of the third component of complement, C3: analysis of the conservation of human CR1, CR2, H and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species. Dev. Comp. Immunol. 16:63-76.
2. Brown, E. J., K. A. Joiner, R. M. Cole, and M. Berger. 1983. Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect. Immun. 39:403-409.
3. Bryant, R. E., and D. E. Jenkins, Jr. 1968. Calcium requirements for complement dependent hemolytic reactions. J. Immunol. 101:664-668.
4. Bulmer, G. S., and M. D. Sans. 1967. Cryptococcus neoformans. II. Phagocytosis by human leukocytes. J. Bacteriol. 94:1480-1483.
5. Bulmer, G. S., and M. D. Sans. 1968. Cryptococcus neoformans. III. Inhibition of phagocytosis. J. Bacteriol. 95:5-8.
6. Casadevall, A., and J. R. Perfect. 1998. Cryptococcus neoformans. ASM Press, Washington, D.C.
7. Chang, Y. C., and K. J. Kwon-Chung. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol. 14:4912-4919.
8. Cherniak, R., E. Reiss, and S. H. Turner. 1982. A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr. Res. 103:239-250.
9. 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin. Diagn. Lab. Immunol. 5:146-159.
10. Cunnion, K. M., H. M. Zhang, and M. M. Frank. 2003. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect. Immun. 71:656-662.
11. Dodds, A. W., and S. K. Law. 1990. The complement component C4 of mammals. Biochem. J. 265:495-502.
12. Duro, R. M., D. Netski, P. Thorkildson, and T. R. Kozel. 2003. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan. Clin. Diagn. Lab. Immunol. 10:252-258.
13. Fine, D. P., S. R. Marney, Jr., D. G. Colley, J. S. Sergent, and R. M. Des Prez. 1972. C3 shunt activation in human serum chelated with EGTA. J. Immunol. 109:807-809.
14. Gates, M. A., P. Thorkildson, and T. R. Kozel. 2004. Molecular architecture of the Cryptococcus neoformans capsule. Mol. Microbiol. 52:13-24.
15. Granger, D. L., J. R. Perfect, and D. T. Durack. 1985. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J. Clin. Investig. 76:508-516.
16. Hammer, C. H., G. H. Wirtz, L. Renfer, H. D. Gresham, and B. F. Tack. 1981. Large scale isolation of functionally active components of the human complement system. J. Biol. Chem. 256:3995-4003.
17. Horstmann, R. D., M. K. Pangburn, and H. J. Müller-Eberhard. 1985. Species specificity of recognition by the alternative pathway of complement. J. Immunol. 134:1101-1104.
18. Houpt, D. C., G. S. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:2857-2864.
19. Joiner, K. A. 1988. Complement evasion by bacteria and parasites. Annu. Rev. Microbiol. 42:201-230.
20. Kozel, T. R. 1977. Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect. Immun. 16:99-106.
21. Kozel, T. R., and R. P. Mastroianni. 1976. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect. Immun. 14:62-67.
22. Kozel, T. R., L. C. Weinhold, and D. M. Lupan. 1996. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect. Immun. 64:3360-3368.
23. Kozel, T. R., M. A. Wilson, and J. W. Murphy. 1991. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect. Immun. 59:3101-3110.
24. Kozel, T. R., M. A. Wilson, G. S. T. Pfrommer, and A. M. Schlageter. 1989. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect. Immun. 57:1922-1927.
25. Kwon-Chung, K. J., and J. C. Rhodes. 1986. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect. Immun. 51:218-223.
26. Law, S. K. A., and A. W. Dodds. 1997. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 6:263-274.
27. MacGill, T. C., R. S. MacGill, A. Casadevall, and T. R. Kozel. 2000. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J. Immunol. 164:4835-4842.
28. Mardiney, M. R., Jr., H. J. Müller-Eberhard, and J. D. Feldman. 1968. Ultrastructural localization of the third and fourth components of complement on complement-cell complexes. Am. J. Pathol. 53:253-260.
29. Pangburn, M. K., and H. J. Müller-Eberhard. 1984. The alternative pathway of complement. Springer Semin. Immunopathol. 7:163-192.
30. Platts-Mills, T. A. E., and K. Ishizaka. 1974. Activation of the alternative pathway of human complement by rabbit cells. J. Immunol. 113:348-357.
31. Sahu, A., T. R. Kozel, and M. K. Pangburn. 1994. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem. J. 302:429-436.
32. Sim, R. B., T. M. Twose, D. S. Paterson, and E. Sim. 1981. The covalent-binding reaction of complement component C3. Biochem. J. 193:115-127.
33. Tack, B. F., and J. W. Prahl. 1976. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry 15:4513-4521.
34. Wilkinson, B. J., S. P. Sisson, Y. Kim, and P. K. Peterson. 1979. Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M: implications for the mechanism of resistance to phagocytosis. Infect. Immun. 26:1159-1163.
35. Wilson, M. A., and T. R. Kozel. 1992. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60:754-761.
36. Zaragoza, O., C. P. Taborda, and A. Casadevall. 2004. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur. J. Immunol. 33:1957-1967.
37. Zhang, M. X., D. M. Lupan, and T. R. Kozel. 1997. Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect. Immun. 65:3822-3827.